Tumor grade improves recurrence prediction in early breast cancer
Part of Cancer, Skin clinical trials.
This study looks at whether looking at tumor grade (how abnormal cells look under a microscope) can improve the accuracy of a genetic test (Oncotype DX) that predicts the risk of breast cancer returning. It aims to help doctors and patients make better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with hormone receptor-positive, HER2-negative early-stage breast cancer.
- You received treatment between January 2011 and December 2023.
- You had the 21-gene Oncotype DX test done, and your results are in your medical records.
- You are at least 20 years old.
- Your cancer had not spread to distant parts of the body (stage IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.